LEASEPassage BIO, Inc. • May 11th, 2020 • Biological products, (no disgnostic substances)
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO PASSAGE BIO, INC. IF PUBLICLY DISCLOSED. PASSAGE BIO PRODUCTS DEVELOPMENT SERVICES AND...Development Services and Clinical Supply Agreement • May 11th, 2020 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS DEVELOPMENT SERVICES AND CLINICAL SUPPLY AGREEMENT (this “Agreement”), dated as of the 13th day of April, 2020 (the “Effective Date”), is entered into by and between PASSAGE BIO, INC., a corporation organized and existing under the Laws of Delaware and having a place of business at 2001 Market Street, Suite 2815, Philadelphia, Pennsylvania 19103 (“Passage Bio”), and CATALENT MARYLAND, INC. (formerly PARAGON BIOSERVICES, INC.), a corporation organized and existing under the Laws of Delaware and having a place of business at 801 West Baltimore Street, Suite 302, Baltimore, Maryland 21201 (“Catalent”). Passage Bio and Catalent are sometimes referred to herein, individually, as a “Party” and, collectively, as the “Parties.”
FIRST AMENDMENT TO LEASEPassage BIO, Inc. • May 11th, 2020 • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO LEASE (“Amendment”) is made and entered into as of ________________, by and between PHILADELPHIA PLAZA - PHASE II LP, a Pennsylvania limited partnership (“Landlord”), and PASSAGE BIO, INC., a Delaware corporation (“Tenant”).
